Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blay, J. Y.
Right arrow Articles by Biron, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blay, J. Y.
Right arrow Articles by Biron, P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal of Clinical Oncology, Vol 16, 864-871, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series

JY Blay, T Conroy, C Chevreau, A Thyss, N Quesnel, H Eghbali, R Bouabdallah, B Coiffier, JP Wagner, A Le Mevel, D Dramais-Marcel, E Baumelou, F Chauvin and P Biron
Centre Leon Berard, Lyon, France. blay@lyon.fnclcc.fr

PURPOSE: The impact of treatment options on survival and late neurologic toxicity was investigated in a series of patients with primary cerebral lymphoma (PCL) and no known cause of immunosuppression. PATIENTS AND METHODS: Prognostic factors for survival and treatment-induced late neurotoxicity were investigated in a retrospective series of 226 patients with PCL. RESULTS: With a median follow-up of 76 months, the median overall survival was 16 months and 5- year survival was 19%. In a univariate analysis, age greater than 60 years, performance status, CSF protein level greater than 0.6 g/L, involvement of corpus callosum or subcortical grey structures, detectable lymphoma cells in CSF, increased serum lactate dehydrogenase (LDH), but not histological subtype, were significantly correlated with a poor survival. Treatment with chemotherapy versus radiotherapy alone (P = .05), high-dose methotrexate (HDMTX; P = .0007), and cytarabine (P = .04) correlated with a better survival in univariate analysis. Using the Cox model, age, performance status, and CSF protein were independently correlated with survival. After adjustment of these factors, treatment with an HDMTX-containing regimen remained the only treatment-related factor independently correlated with survival (P = .01). The projected incidence of treatment-induced late neurotoxicity was 26% at 6 years in this series, with a median survival from the diagnosis of late neurotoxicity of 12 months. Treatment with radiotherapy followed by chemotherapy was the only parameter correlated with late neurotoxicity in multivariate analysis (relative risk, 11.5; P = .0007). CONCLUSION: Patients with PCL treated with regimens that included HDMTX followed by radiotherapy have an improved survival, but not a higher risk of late neurotoxicity as compared with other treatment modalities in this series.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
H. Ghesquieres, C. Ferlay, C. Sebban, D. Perol, A. Bosly, O. Casasnovas, O. Reman, B. Coiffier, H. Tilly, P. Morel, et al.
Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Ann. Onc., November 18, 2009; (2009) mdp529v2.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Angelov, N. D. Doolittle, D. F. Kraemer, T. Siegal, G. H. Barnett, D. M. Peereboom, G. Stevens, J. McGregor, K. Jahnke, C. A. Lacy, et al.
Blood-Brain Barrier Disruption and Intra-Arterial Methotrexate-Based Therapy for Newly Diagnosed Primary CNS Lymphoma: A Multi-Institutional Experience
J. Clin. Oncol., July 20, 2009; 27(21): 3503 - 3509.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
K. Jahnke, L. L. Muldoon, C. G. Varallyay, S. J. Lewin, R. D. Brown, D. F. Kraemer, C. Soussain, and E. A. Neuwelt
Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma
Neuro-oncol, January 1, 2009; 11(5): 503 - 513.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
Y. Shibamoto, H. Ogino, G. Suzuki, M. Takemoto, N. Araki, K. Isobe, E. Tsuchida, K. Nakamura, M. Kenjo, K. Suzuki, et al.
Primary central nervous system lymphoma in Japan: Changes in clinical features, treatment, and prognosis during 1985-2004
Neuro-oncol, August 1, 2008; 10(4): 560 - 568.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Roy, S. A. Josephson, J. Fridlyand, J. Karch, C. Kadoch, J. Karrim, L. Damon, P. Treseler, S. Kunwar, M. A. Shuman, et al.
Protein Biomarker Identification in the CSF of Patients With CNS Lymphoma
J. Clin. Oncol., January 1, 2008; 26(1): 96 - 105.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Correa, L Maron, H Harder, M Klein, C. Armstrong, P Calabrese, J. Bromberg, L. Abrey, T. Batchelor, and D Schiff
Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines
Ann. Onc., July 1, 2007; 18(7): 1145 - 1151.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Jahnke, M. Hummel, A. Korfel, T. Burmeister, P. Kiewe, H. A. Klasen, H.-H. Muller, H. Stein, and E. Thiel
Detection of Subclinical Systemic Disease in Primary CNS Lymphoma by Polymerase Chain Reaction of the Rearranged Immunoglobulin Heavy-Chain Genes
J. Clin. Oncol., October 10, 2006; 24(29): 4754 - 4757.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Illerhaus, R. Marks, G. Ihorst, R. Guttenberger, C. Ostertag, G. Derigs, N. Frickhofen, F. Feuerhake, B. Volk, and J. Finke
High-Dose Chemotherapy With Autologous Stem-Cell Transplantation and Hyperfractionated Radiotherapy As First-Line Treatment of Primary CNS Lymphoma
J. Clin. Oncol., August 20, 2006; 24(24): 3865 - 3870.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. Fischer, E. Thiel, H.-A. Klasen, J. Birkmann, K. Jahnke, P. Martus, and A. Korfel
Prospective trial on topotecan salvage therapy in primary CNS lymphoma
Ann. Onc., July 1, 2006; 17(7): 1141 - 1145.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Batchelor and J. S. Loeffler
Primary CNS Lymphoma
J. Clin. Oncol., March 10, 2006; 24(8): 1281 - 1288.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
A. M. P. Omuro, L. S. Ben-Porat, K. S. Panageas, A. K. Kim, D. D. Correa, J. Yahalom, L. M. DeAngelis, and L. E. Abrey
Delayed Neurotoxicity in Primary Central Nervous System Lymphoma
Arch Neurol, October 1, 2005; 62(10): 1595 - 1600.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
K. Fliessbach, C. Helmstaedter, H. Urbach, A. Althaus, H. Pels, M. Linnebank, A. Juergens, A. Glasmacher, I. G. Schmidt-Wolf, T. Klockgether, et al.
Neuropsychological outcome after chemotherapy for primary CNS lymphoma: A prospective study
Neurology, April 12, 2005; 64(7): 1184 - 1188.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. N. Shenkier, J.-Y. Blay, B. P. O'Neill, P. Poortmans, E. Thiel, K. Jahnke, L. E. Abrey, E. Neuwelt, R. Tsang, T. Batchelor, et al.
Primary CNS Lymphoma of T-Cell Origin: A Descriptive Analysis From the International Primary CNS Lymphoma Collaborative Group
J. Clin. Oncol., April 1, 2005; 23(10): 2233 - 2239.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. Jahnke, A. Korfel, P. Martus, M. Weller, U. Herrlinger, A. Schmittel, L. Fischer, E. Thiel, and On behalf of the German Primary Central Nervous Sy
High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma
Ann. Onc., March 1, 2005; 16(3): 445 - 449.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Neuroradiol.Home page
E. A. Neuwelt, P. E. Guastadisegni, P. Varallyay, and N. D. Doolittle
Imaging Changes and Cognitive Outcome in Primary CNS Lymphoma after Enhanced Chemotherapy Delivery
AJNR Am. J. Neuroradiol., February 1, 2005; 26(2): 258 - 265.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
T. T. Batchelor, B. R. Buchbinder, and N. L. Harris
Case 1-2005 - A 35-Year-Old Woman with Difficulty Walking, Headache, and Nausea
N. Engl. J. Med., January 13, 2005; 352(2): 185 - 194.
[Full Text] [PDF]

Home page
 NeurologyHome page
L. Fischer, E. Thiel, H. A. Klasen, H. Kirchen, K. Jahnke, and A. Korfel
Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan
Neurology, May 25, 2004; 62(10): 1885 - 1887.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Reni and A. J.M. Ferreri
Is Withdrawal of Consolidation Radiotherapy an Evidence-Based Strategy in Primary Central Nervous System Lymphomas?
J. Clin. Oncol., March 15, 2004; 22(6): 1165 - 1167.
[Full Text] [PDF]

Home page
 NeurologyHome page
H. Harder, H. Holtel, J. E.C. Bromberg, P. Poortmans, H. Haaxma-Reiche, H. C. Kluin-Nelemans, J. Menten, and M. J. van den Bent
Cognitive status and quality of life after treatment for primary CNS lymphoma
Neurology, February 24, 2004; 62(4): 544 - 547.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. M.P. Poortmans, H. C. Kluin-Nelemans, H. Haaxma-Reiche, M. Van't Veer, M. Hansen, P. Soubeyran, M. Taphoorn, J. Thomas, M. Van den Bent, M. Fickers, et al.
High-Dose Methotrexate-Based Chemotherapy Followed by Consolidating Radiotherapy in Non-AIDS-Related Primary Central Nervous System Lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962
J. Clin. Oncol., December 15, 2003; 21(24): 4483 - 4488.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Pels, I. G.H. Schmidt-Wolf, A. Glasmacher, H. Schulz, A. Engert, V. Diehl, A. Zellner, G. Schackert, H. Reichmann, F. Kroschinsky, et al.
Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred Radiotherapy
J. Clin. Oncol., December 15, 2003; 21(24): 4489 - 4495.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
H. Ishikawa, M. Hasegawa, Y. Tamaki, K. Hayakawa, T. Akimoto, H. Sakurai, N. Mitsuhashi, H. Niibe, M. Tamura, and T. Nakano
Comparable Outcomes of Radiation Therapy without High-dose Methotrexate for Patients with Primary Central Nervous System Lymphoma
Jpn. J. Clin. Oncol., September 1, 2003; 33(9): 443 - 449.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. J.M. Ferreri, L. E. Abrey, J.-Y. Blay, B. Borisch, J. Hochman, E. A. Neuwelt, J. Yahalom, E. Zucca, F. Cavalli, J. Armitage, et al.
Summary Statement on Primary Central Nervous System Lymphomas From the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002
J. Clin. Oncol., June 15, 2003; 21(12): 2407 - 2414.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. M. Braaten, R. A. Betensky, L. de Leval, Y. Okada, F. H. Hochberg, D. N. Louis, N. L. Harris, and T. T. Batchelor
BCL-6 Expression Predicts Improved Survival in Patients with Primary Central Nervous System Lymphoma
Clin. Cancer Res., March 1, 2003; 9(3): 1063 - 1069.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. J.M. Ferreri, J.-Y. Blay, M. Reni, F. Pasini, M. Spina, A. Ambrosetti, A. Calderoni, A. Rossi, V. Vavassori, A. Conconi, et al.
Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience
J. Clin. Oncol., January 15, 2003; 21(2): 266 - 272.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A multicenter study of treatment of primary CNS lymphoma
Neurology, May 28, 2002; 58(10): 1513 - 1520.


Home page
 JCOHome page
E. M. Bessell, A. Lopez-Guillermo, S. Villa, E. Verger, B. Nomdedeu, J. Petit, P. Byrne, E. Montserrat, and F. Graus
Importance of Radiotherapy in the Outcome of Patients With Primary CNS Lymphoma: An Analysis of the CHOD/BVAM Regimen Followed by Two Different Radiotherapy Treatments
J. Clin. Oncol., January 1, 2002; 20(1): 231 - 236.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Giustina, M. Gola, M. Doga, and E. A. Rosei
Primary Lymphoma of the Pituitary: An Emerging Clinical Entity
J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4567 - 4575.
[Full Text] [PDF]

Home page
 JCOHome page
C. Soussain, F. Suzan, K. Hoang-Xuan, N. Cassoux, V. Levy, N. Azar, C. Belanger, E. Achour, V. Ribrag, S. Gerber, et al.
Results of Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue in 22 Patients With Refractory or Recurrent Primary CNS Lymphoma or Intraocular Lymphoma
J. Clin. Oncol., February 1, 2001; 19(3): 742 - 749.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
L. M. DeAngelis
Brain Tumors
N. Engl. J. Med., January 11, 2001; 344(2): 114 - 123.
[Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
N. D. Doolittle, C. P. Anderson, W. A. Bleyer, J. G. Cairncross, T. Cloughesy, S. L. Eck, P. Guastadisegni, W. A. Hall, L. L. Muldoon, S. J. Patel, et al.
Importance of dose intensity in neurooncology clinical trials: Summary Report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium
Neuro-oncol, January 1, 2001; 3(1): 46 - 54.
[Abstract] [PDF]

Home page
 NeurologyHome page
U. Herrlinger, W. Brugger, M. Bamberg, W. Kuker, J. Dichgans, and M. Weller
PCV salvage chemotherapy for recurrent primary CNS lymphoma
Neurology, April 25, 2000; 54(8): 1707 - 1708.
[Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
S. Ng, M. A. Rosenthal, D. Ashley, and L. Cher
High-dose methotrexate for primary CNS lymphoma in the elderly
Neuro-oncol, January 1, 2000; 2(1): 40 - 44.
[Abstract] [PDF]

Home page
 Neuro Oncol DukeHome page
B. P. O'Neill, C.-H. Wang, J. R. O'Fallon, J. P. Colgan, J. D. Earle, R. L. Krigel, L. D. Brown, and W. J. McGinnis
The consequences of treatment and disease in patients with primary CNS non-Hodgkin's lymphoma: Cognitive function and performance status
Neuro-oncol, July 1, 1999; 1(3): 196 - 203.
[Abstract] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
L. M DeANGELIS
Primary central nervous system lymphoma
J. Neurol. Neurosurg. Psychiatry, June 1, 1999; 66(6): 699 - 701.
[Full Text]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1998 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online